Terlipressin

Generic Name
Terlipressin
Brand Names
Terlivaz
Drug Type
Biotech
Chemical Formula
-
CAS Number
14636-12-5
Unique Ingredient Identifier
7Z5X49W53P
Background

Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in vari...

Indication

Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.

Associated Conditions
Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
Associated Therapies
-
Clinical Trials
Related News

Vasoactive Drugs in Real World Practice

First Posted Date
2016-05-02
Last Posted Date
2016-05-03
Lead Sponsor
Kaohsiung Veterans General Hospital.
Target Recruit Count
150
Registration Number
NCT02757703
Locations
🇨🇳

Division of Gastroenterology, Department of Internal Medicine, Kaohsiung, Taiwan

Decision Support for Intraoperative Low Blood Pressure

Not Applicable
Completed
Conditions
Hypotension
Interventions
Procedure: Attending real-time decision support
Procedure: In-room real-time decision support
Procedure: Attending feedback emails
Procedure: In-room provider feedback emails
Device: Anesthesia Information Management System (AIMS)
Device: Perioperative Data Warehouse (PDW)
Procedure: General anesthesia
Device: Pager system
Procedure: Central neuraxial anesthesia
Procedure: Non-cardiac surgery
Drug: Propofol
Drug: Sevoflurane
Drug: Desflurane
Drug: Isoflurane
Drug: Ephedrine
Drug: Phenylephrine
Drug: Norepinephrine
Drug: Epinephrine
Drug: Dobutamine
Drug: Dopamine
Drug: Isoproterenol
Drug: Milrinone
Drug: Atropine
Drug: Glycopyrrolate
Drug: Vasopressin
Drug: Terlipressin
Drug: Sodium Chloride 0.9%
Drug: Ringer's lactate
Drug: Hydroxyethyl starch solutions
Drug: Fresh Frozen Plasma
Drug: Packed Red Blood Cells
Drug: Albumin solutions
Drug: Plasma-Lyte
Drug: Lidocaine
Drug: Bupivacaine
Drug: Levobupivacaine
Drug: Ropivacaine
Drug: Mepivacaine
Drug: Tetracaine
Drug: Prilocaine
Drug: Procaine
Drug: Chloroprocaine
Drug: Benzocaine
Drug: Articaine
First Posted Date
2016-04-04
Last Posted Date
2019-05-16
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
22435
Registration Number
NCT02726620
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery

First Posted Date
2016-03-24
Last Posted Date
2017-12-19
Lead Sponsor
Assiut University
Target Recruit Count
50
Registration Number
NCT02718599
Locations
🇪🇬

Assiut University hospital, Assiut, Asyut Governorate, Egypt

To Assess Safety and Efficacy of Bolus Versus Continuous Infusion of Terlipressin in Acute Variceal Bleeding

Not Applicable
Completed
Conditions
Acute Variceal Bleeding
Interventions
Drug: Terlipressin
First Posted Date
2016-03-01
Last Posted Date
2019-09-04
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Target Recruit Count
110
Registration Number
NCT02695862
Locations
🇮🇳

Institute of liver and Biliary Sciences, New Delhi, Delhi, India

Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.

First Posted Date
2015-10-28
Last Posted Date
2017-12-27
Lead Sponsor
Assiut University
Target Recruit Count
84
Registration Number
NCT02588716
Locations
🇪🇬

Assiut University hospital, Assiut, Asyut Governorate, Egypt

The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure

Phase 4
Conditions
Hepatorenal Syndrome
Interventions
Drug: Terlipressin
First Posted Date
2015-07-03
Last Posted Date
2015-07-03
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
30
Registration Number
NCT02489864
Locations
🇨🇳

The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

Does Terlipressin Improve Renal Outcome After Liver Surgery

Phase 2
Withdrawn
Conditions
Kidney Failure
Interventions
Drug: Placebo
Drug: Terlipressin
First Posted Date
2015-02-23
Last Posted Date
2017-05-05
Lead Sponsor
University of Zurich
Registration Number
NCT02368249
Locations
🇨🇭

Department of Visceral and Transplantation Surgery of the University Hospital of Zurich, Zurich, Switzerland

Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails

First Posted Date
2014-12-08
Last Posted Date
2014-12-08
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
1320
Registration Number
NCT02311608
Locations
🇨🇳

Zhongshan Hospital, Shanghai, Shanghai, China

The Effect of Terlipressin on Intesitnal Function in Septic Shock Patients

First Posted Date
2014-12-03
Last Posted Date
2014-12-30
Lead Sponsor
Liu ZiMeng
Target Recruit Count
40
Registration Number
NCT02306239
Locations
🇨🇳

the First Affiliated Hospital of Sumyetsan University, Guangzhou, Guangdong, China

Hemodynamic Effects of Terlipressin and High Dose Octreotide

First Posted Date
2014-04-22
Last Posted Date
2016-06-13
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
88
Registration Number
NCT02119884
Locations
🇨🇳

180 Fenglin Road, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy